Structural Basis of the Main Proteases of Coronavirus Bound to Drug Candidate PF-07321332

Abstract excerpt

The current pandemic of multiple variants has created an urgent need for effective inhibitors of SARS-CoV-2 to complement vaccine strategies. PF-07321332, developed by Pfizer, is the first orally administered coronavirus-specific main protease inhibitor approved by the FDA. We solved the crystal structures of the main protease of SARS-CoV-2, SARS-CoV, and MERS-CoV that bound to the PF-07321332, suggesting...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Computational Drug Discovery Methods
• Share to COVID-19 Clinical Research Studies
• Share to SARS-CoV-2 and COVID-19 Research